Search clinical trials for: Idalopirdine (Lu AE58054) 60 mg

Total 344 results

H. Lundbeck A/S

Completed

Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function

Alzheimer Disease

Germany
H. Lundbeck A/S

Completed

Bioequivalence Study of Idalopirdine Tablets 60 mg

Healthy

United Kingdom
H. Lundbeck A/S

Terminated

Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease

Alzheimer's Disease

United States
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor (STARBRIGHT)

Alzheimer's Disease

United States, Australia, Brazil, Czechia, Germany, Israel, Korea, Republic of, Mexico, Serbia, Singapore, Slovakia, Spain, Switzerland, Turkey, United Kingdom
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil (STARBEAM)

Alzheimer's Disease

United States, Argentina, Brazil, Canada, Croatia, Czechia, Estonia, Finland, France, Hungary, Israel, Italy, Korea, Republic of, Lithuania, Poland, Portugal, Taiwan, United Kingdom, Ireland
H. Lundbeck A/S

Completed

Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects

Healthy

United Kingdom
H. Lundbeck A/S

Completed

Absolute Bioavailability of Lu AE58054 in Healthy Subjects

Healthy

United Kingdom
H. Lundbeck A/S

Completed

Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine

Healthy

United Kingdom
H. Lundbeck A/S

Completed

Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease (STAR Extension)

Alzheimer's Disease

Germany, United States, Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, France, Hungary, Israel, Italy, Korea, Republic of, Lithuania, Poland, Portugal, Romania, South Africa, Spain, Taiwan and more
H. Lundbeck A/S

Completed

Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects

Heptic Impairment

Germany
H. Lundbeck A/S

Completed

Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease

Alzheimer's Disease

Spain, Germany, Australia, Canada, Czech Republic, Italy, Poland
H. Lundbeck A/S

Completed

Effect of Multiple Doses of Itraconazole on the Multiple Dose Pharmacokinetics of Lu AE58054 in Healthy Subjects

Healthy Volunteers

France
H. Lundbeck A/S

Completed

Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia

Schizophrenia | Cognition

Hong Kong, Thailand, Belgium, France, Germany, Italy, Poland, Taiwan
H. Lundbeck A/S

Completed

Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy Men

Healthy Volunteers

France
H. Lundbeck A/S

Completed

An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

Parkinson Disease

United States
H. Lundbeck A/S

Completed

Bioequivalence Study of Lu AF35700

Healthy

United Kingdom
Vifor (International) Inc.
Labcorp Drug Development Inc

Withdrawn

Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia

Beta-Thalassemia

United States, Bulgaria, Israel
Grünenthal GmbH

Completed

A Clinical Study in Healthy Women Which Aims to Explore the Intestinal Uptake of Two Different Tablets of GRTA9906 Into the Body and the Effect of Food on it

Pain | Chronic Pain | Neuropathic Pain | Visceral Pain

Germany
H. Lundbeck A/S

Terminated

Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia

Schizophrenia

Bulgaria, Czechia, Estonia, Germany, Hungary, Latvia, Poland, Ukraine
Suzhou Kintor Pharmaceutical Inc,

Completed

Phase II Study Evaluating the Efficacy and Safety of KX-826

Androgenetic Alopecia (AGA)

China
Sobi, Inc.

Terminated

Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure

Thrombocytopenia

United States
University of Florence
Azienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaborators

Recruiting

Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients (STAR)

Migraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura

Italy
AbbVie

Completed

A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine

Chronic Migraine | Episodic Migraine

Japan
AbbVie

Active, not recruiting

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

Chronic Migraine | Episodic Migraine

United States, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Spain, Taiwan, United Kingdom
GlaxoSmithKline

Completed

Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)

Arthritis, Rheumatoid

Spain, Germany, Russian Federation, United Kingdom, Italy, Poland
Allergan

Completed

Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. (ELEVATE)

Episodic Migraine

United States, Australia, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Russian Federation, Spain, Sweden, United Kingdom
Allergan

Completed

Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

Chronic Migraine

United States, Australia, Canada, China, Czechia, Denmark, France, Germany, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Spain, Sweden, Taiwan, United Kingdom
Hoffmann-La Roche

Recruiting

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.

Huntington Disease

United States, France, Australia, Switzerland, Spain, New Zealand, Germany, Argentina, United Kingdom, Poland, Italy, Denmark, Portugal, Canada, Austria
PHARMENTERPRISES LLC

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers

Influenza | Acute Respiratory Infection

Russian Federation
University of Bologna
Ipsen; Bioikos Ambiente Srl; AOU S.Orsola Malpighi-Unit of Oncologic Molecular... and other collaborators

Unknown

Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA)

Non Small Cell Lung Cancer

Italy
University of Washington
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac Arrest (SNOCAT)

Out-Of-Hospital Cardiac Arrest

United States
Shionogi
Hormos Medical; QuatRx Pharmaceuticals

Completed

A Clinical Study to Evaluate the Safety of Ospemifene

Atrophy | Vaginal Diseases
Shionogi
Hormos Medical; QuatRx Pharmaceuticals

Completed

Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity

Atrophy | Vaginal Diseases
H. Lundbeck A/S

Completed

A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects

Healthy

United Kingdom
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)

Cellulite

United States
Guangzhou Magpie Pharmaceuticals Co., Ltd.

Not yet recruiting

A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 Tablets

Pulmonary Arterial Hypertension
Taisho Pharmaceutical Co., Ltd.

Recruiting

A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Hyperphosphatemia Patients on Hemodialysis

Japan
Bial R&D Investments, S.A.

Active, not recruiting

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE)

Parkinson's Disease

United States, Spain, Netherlands, France, Italy, Germany, Portugal, United Kingdom, Canada, Poland, Sweden
GlaxoSmithKline

Completed

A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets.

Schizophrenia

United Kingdom
Exelixis

Active, not recruiting

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER)

Medullary Thyroid Cancer

Australia, France, Israel, Spain, Russian Federation, Netherlands, Hungary, Korea, Republic of, Croatia, Italy, Canada, Poland, Romania, Sweden
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR

Lung Adenocarcinoma
Pfizer

Completed

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

Obesity | Overweight

United States
Hospital do Coracao

Completed

Antiviral Agents Against COVID-19 Infection (REVOLUTIOn)

COVID-19

Brazil
GlaxoSmithKline

Completed

First Time in Human Study Using GSK2330672

Diabetes Mellitus, Type 2

United States
Istituto Clinico Humanitas

Recruiting

Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma (Immunocabo)

Hepatocarcinoma

Italy
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults

Healthy

United States
American University of Beirut Medical Center
Takeda

Completed

An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan

GERD | Proton Pump Inhibitor

Lebanon
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease

Huntington's Disease

Canada, United Kingdom, Germany
Pfizer
Syneos Health

Completed

A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers

Healthy

Canada
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Chemoprophylactic Activity of M5717 in PfSPZ Challenge Model

Healthy

Netherlands

Search clinical trials for: Idalopirdine (Lu AE58054) 60 mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations